Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Rules on Centralised Authorisation for Device Trials in Germany Continue to Frustrate Industry

This article was originally published in RAJ Devices

Executive Summary

Medical technology firms in Germany see recent regulatory and political changes in their country as largely positive, with one or two exceptions. Tobias Weiler, head of the medical technology department of industry association Spectaris, tells Ashley Yeo about his hopes and fears for the industry.

You may also be interested in...



Philips Delivers On Aim To Focus Exclusively On Health And Healthtech

Royal Philips is planning to sell its domestic appliance business to better focus on its strategic aims in health technology. The group made the announcement as it unveiled 2019 sales up 4.5% on a comparable basis.

UK Readies Medtech And Pharma Sectors For Regulatory Life Outside The EU

Work has started on UK-only regulations for the medtech and medicines sectors, to ensure that the regulatory framework not only functions but can also react swiftly to needs after the UK leaves the EU. This article is part two of two.

Progress And Pitfalls Ahead As UK Medtech Faces A Year Of Leaving The EU

As the UK enters the final week of its 47-year membership of the EU, UK medtech industry and commentators look ahead to the routes beyond Brexit for the UK, and a likely intense and often rocky 11 months of trade deal negotiations with EU and global partners. This article is part one of two.

UsernamePublicRestriction

Register

SC096158

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel